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Abstract Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemo-
lytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early
diagnosis and timely initiation of appropriate treatment for aHUS. Recent clinical and molecular findings have
resulted in several proposed classifications and definitions of thrombotic microangiopathy and aHUS. Based on
recent advances in this field and the emerging international consensus to exclude secondary TMAs from the defini-
tion of aHUS, we have redefined aHUS and proposed diagnostic algorithms, differential diagnosis, and therapeutic
strategies for aHUS.
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Thrombotic microangiopathy (TMA) is a pathophysiological
process characterized by the triad of microangiopathic hemoly-
tic anemia (MAHA), consumptive thrombocytopenia, and pla-
telet-mediated microvascular occlusion, leading to organ
failure. Classic forms of TMA include hemolytic uremic syn-
drome (HUS) and thrombotic thrombocytopenic purpura
(TTP). TMAs caused by Shiga toxin–producing Escherichia
coli (STEC) are termed STEC-HUS, while TMAs caused by
severely reduced activity (levels less than 10% of normal) of a
disintegrin-like metalloproteinase with thrombospondin type 1
repeat motifs 13 (ADAMTS13) are termed TTP.
Approximately 90% of patients presenting with HUS symp-
toms have STEC infection with bloody diarrhea. The remain-
ing 10% do not present with diarrhea and their samples are
negative for Shiga toxins; such cases were previously classi-
fied as diarrhea-negative HUS (D(-)HUS). In 1981, the first
case of D(-)HUS accompanied by complement factor H (CFH)
deficiency was reported.1 Warwicker et al.2 suggested CFH
gene mutations as a possible cause of HUS in a linkage analy-
sis study performed in 1998, one of the earliest works to pro-
pose genetic involvement in atypical HUS (aHUS).
Subsequently, a series of studies indicated that aHUS patho-
genesis involved genetic abnormalities of the complements,
such as C3, complement factor B (CFB), complement factor I
(CFI), membrane cofactor protein (MCP or CD46), and
thrombomodulin (THBD). In addition, an acquired form of
aHUS with positive anti-CFH antibodies has been identified.
Patients with aHUS have also been reported in Japan,3 and
a series of cases prompted the Japanese Society of Nephrology
and the Japan Pediatric Society to jointly develop the aHUS
diagnostic criteria in 2013.4,5 These criteria broadly defined
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aHUS as a TMA condition unrelated to STEC-HUS or TTP;
thus, the definition included aHUS with complement regula-
tion abnormality and TMA with coexisting diseases (sec-
ondary TMA; also called other TMA). However, the
international consensus to exclude secondary TMAs from the
definition of aHUS6–8 suggested the need to revise the 2013
edition. This article explains the diagnosis and treatment
guides for aHUS, which have incorporated diagnostic algo-
rithms and therapeutic recommendations to assist in clinical
practice.
Definitions of TMA and aHUS
Originally, TMA was used to describe pathologic conditions
involving systemic microvascular thrombosis and endothelial
injury. Currently, TMA also refers to the clinical conditions with
the triad of MAHA, consumptive thrombocytopenia, and platelet-
mediated microvascular occlusion, leading to organ failures.
Common forms of TMA include TTP, STEC-HUS, complement-
related aHUS, and secondary TMA. Different types of TMA
cause thrombosis in preferential organs, and renal impairment is
the most frequent with STEC-HUS and aHUS.
There is currently no international consensus regarding the
classification of diseases under TMA. According to the defini-
tion of the aHUS diagnostic criteria jointly proposed by the
Japanese Society of Nephrology and the Japan Pediatric Soci-
ety in 2013, aHUS involved the triad of MAHA, thrombocy-
topenia, and acute kidney failure in the absence of Shiga
toxins and TTP.4,5
Quoting the diagnostic criteria established by the UK aHUS
Rare Disease Group, Scully and Goodship7 proposed to
exclude the following from aHUS: STEC-HUS, TTP, and sec-
ondary TMAs resulting from drugs, infection, transplantation,
cobalamin deficiency, systemic lupus erythematosus, antiphos-
pholipid syndrome, scleroderma, and other causes.
The definitions of aHUS and TMA have been considerably
revised in the current aHUS clinical guides, based on findings
reported by several publications.7–9 Specifically, aHUS associ-
ated with congenital and acquired “complement regulation
abnormality”, as defined in the 2013 version, has been termed
“aHUS (complement-mediated HUS)” in the current edition.
In addition, TMAs arising from other causes have been
defined as “secondary TMAs.”
More specifically, aHUS defined in the current version
relates to one of the following:
1. Congenital genetic abnormalities (known as of 2015) in
seven complement component and complement regulatory
genes; i.e., abnormalities in the CFH, CFI, CD46 (MCP),
C3, CFB, THBD, and diacylglycerol kinase e (DGKE)
genes. Note that several researchers do not regard DGKE
abnormalities as a cause of aHUS because of the absence
of compelling evidence of the interplay between the
DGKE and complement systems. Further, plasminogen
(PLG) gene mutations have been suggested to contribute
to the etiology of aHUS, but warrant further investigation.
2. Anti-CFH autoantibody positivity (a cause of acquired
aHUS).
3. Patients who have none of the genetic mutations men-
tioned above, but whose clinical manifestations suggest
aHUS that cannot be classified as STEC-HUS, TTP, or
secondary TMA.
Epidemiology
The exact incidence rates of aHUS are unknown. It is esti-
mated that 2 per million adults and 3.3 per million children
develop aHUS each year.10 Approximately 40% of patients
who are newly diagnosed with aHUS are under 18 years of
age.9,11 A 1-year prospective study conducted in the United
Kingdom reported that the incidence rate was 0.4 patients per
million population.12 In Japan, current estimates suggest that
100–200 patients are diagnosed with aHUS.
Etiology and pathophysiology
Complement-mediated HUS is caused by dysregulation of the
alternative pathway of the complement system. The genetic
causes of aHUS can be divided into loss-of-function and gain-
of-function mutations. Loss-of-function mutations relate to the
CFH, CFI, CD46, and THBD genes. Anti-CFH antibody also
results in CFH dysfunction. Gain-of-function mutations relate
to the CFB and C3 genes. Loss-of-function and gain-of-func-
tion mutations both cause hyperactivation of the alternative
complement pathway, which in turn induces aHUS by trigger-
ing endothelial damage and platelet aggregation.
Anti-CFH autoantibodies have been detected in approxi-
mately 10% of patients with aHUS.13 These antibodies bind to
the C-terminal domain of CFH and impair CFH-mediated cell
surface protection by interfering with the interaction between
CFH and its surface ligands.
Recent genetic studies of patients with TMA have identi-
fied abnormalities in the THBD, DGKE, and PLG encoding
components of the coagulation and fibrinolytic pathways.14,15
However, the details of the involvement of these mutations in
TMA pathogenesis remain to be clarified. While THBD is a
key mediator of anticoagulant response, it also induces C3b
inactivation by binding to C3b or CFH. In the current clinical
guides, patients with THBD, DGKE, and PLG abnormalities
are categorized as having aHUS.
Diagnosis
Clinical manifestations
According to a UK national survey, the onset of many cases
of aHUS is either idiopathic or secondary to infection and
other disease triggers.16 Similar to STEC-HUS, aHUS is fre-
quently accompanied by hemolytic anemia, thrombocytopenia,
and renal failure. The clinical manifestations may also include
central neuropathy, cardiac failure, respiratory disorders, ente-
rocolitis, hypertension, and other conditions affecting multiple
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organs or systems. Patients with aHUS may present with
ischemic enterocolitis and other gastrointestinal problems. In
addition, aHUS may be precipitated by microbial or viral
infections of the digestive system. Therefore, attention should
be paid to the fact that the presence of diarrhea does not
exclude the diagnosis of aHUS.16
Clinical diagnostic criteria
Patients with TMA are clinically diagnosed with aHUS if the
following diagnoses can be excluded: STEC-HUS, TTP, TMA
secondary to metabolism-related, infection, drug-induced,
autoimmune diseases, malignant tumors, hemolysis, elevated
liver enzymes, and low platelets (HELLP) syndrome, trans-
plantation, or other known causes. TMA typically, but not
necessarily, involves the following conditions:
1. MAHA with hemoglobin levels below 10 g/dL. In addition
to blood hemoglobin levels, elevation of serum lactate
dehydrogenase (LDH) level, notable decrease of serum hap-
toglobin level, and the presence of schistocytes on a periph-
eral blood smear should be taken into consideration to
confirm the diagnosis of MAHA. Detection of schistocytes
is not a necessary criterion for diagnosis of MAHA.
2. Thrombocytopenia with platelet counts less than 150 000/
lL.9
3. Acute kidney injury (AKI). In pediatric patients, AKI is
defined as serum creatinine levels at least 1.5 times the upper
limit of the age- and sex-specific pediatric reference range
defined by the Japanese Society for Pediatric Nephrology.17
For adult patients, the diagnosis of AKI should be made
according to well-established diagnostic guidelines.18
Differential diagnosis
Patients with TMA should be clinically diagnosed with aHUS
after confirming that they do not meet the criteria for the follow-
ing: first, STEC-HUS or TTP, and then, TMA secondary to
known causative underlying conditions.7,19 It should be noted
that some cases of secondary TMA have been reported to have
complement gene mutations and anti-CFH antibodies. Future
research should investigate the extent of the involvement of
abnormal complement activation in the etiology of secondary
TMA, the proportion of patients with complement gene muta-
tions among the population with secondary TMA, and the effec-
tiveness of eculizumab for treating secondary TMA.
Clinicians should strongly suspect aHUS if the patient’s
family history includes individuals with the following diag-
noses: aHUS; HUS, TTP, or TMA in the era when aHUS was
not well recognized; or renal failure of unknown cause.
Differentiation between TMA and Similar Conditions
• Diagnosis of hemolytic anemia and differentiation of
MAHA from other forms of hemolytic anemia. Elevated
LDH level, schistocytes in blood smears, and marked
decreases in haptoglobin levels are consistent with the
diagnosis of hemolytic anemia. The Coombs test is helpful
in diagnosing autoimmune hemolytic anemia.
• Differentiation between TMA and other disorders causing
AKI.
• Differentiation of disseminated intravascular coagulation
(DIC). Physicians should use well-established diagnostic
criteria for DIC. For this purpose, appropriate parameters
should be evaluated, such as prothrombin time (PT), acti-
vated partial thromboplastin time (APTT), and fibrin
degradation product (FDP), D-dimer, and fibrinogen levels.
In general, DIC occurs secondary to sepsis, malignant
tumors, hematologic disorders, trauma, and other underly-
ing causes.
• Differentiation of pernicious anemia. Pernicious anemia
has been reported to present with clinical manifestations
similar to those of TMA.20 Measurements of vitamin B12
and folic acid levels are helpful for its identification.
Patients with pernicious anemia frequently have low reticu-
locyte counts.
• Differentiation of heparin-induced thrombocytopenia
(HIT).
Differentiation of STEC-HUS
Results of stool culture assays, direct detection of Shiga toxins
in feces, and anti-lipopolysaccharide (LPS) immunoglobulin
(Ig) M antibody measurements assist the diagnosis of STEC
infection. Approximately 80% of patients with STEC-HUS
have bloody diarrhea, which is often severe. Ultrasound scans
typically show extreme wall thickening of the ascending colon
with elevated echogenicity. In pediatric patients, STEC-HUS
accounts for approximately 90% of all TMA cases. Therefore,
STEC-HUS should be primarily suspected in children aged
6 months or older presenting with severe bloody diarrhea and
other common gastrointestinal complications.
Differentiation of TTP
Patients who have less than 10% of normal ADAMTS13 activity
and are positive for anti-ADAMTS13 neutralizing antibodies (in-
hibitors) are diagnosed with acquired TTP. Congenital TTP is
suspected if ADAMTS13 activity is less than 10% and anti-
ADAMTS13 inhibitors are not present.21 To confirm the diagno-
sis of congenital TTP, ADAMST13 gene analysis is necessary.
TMAs other than TTP, such as aHUS, HUS, and secondary
TMA, are occasionally associated with decreased ADAMTS13
activity; however, in most such cases, ADAMTS13 activity does
not decrease below 20% of normal.22
Differentiation of Secondary TMA
• Cobalamin C deficiency (particularly in infants). Disorders
of cobalamin metabolism are frequently detected in infants
© 2016 Japan Pediatric Society and Japanese Society of Nephrology. Pediatrics International published by John Wiley & Sons Australia, Ltd on behalf of Japan Pediatric Society
Clinical Guides for aHUS 551
less than 12 months of age presenting with feeding prob-
lems, vomiting, poor growth, enervation, hypotonia, and
convulsions. Cobalamin C deficiency has also been
reported in adults in recent years. This disease presents
with hyperhomocysteinemia, decreased plasma methionine
levels, and methylmalonic aciduria.23
• Autoimmune diseases and connective tissue diseases, in
particular, systemic lupus erythematosus, scleroderma renal
crisis, antiphospholipid syndrome, multiple myositis/der-
matomyositis, and vasculitis. These disorders often present
with signs and symptoms similar to TMA. The following
assessments should be conducted, as appropriate: antinu-
clear antibodies, antiphospholipid antibodies, anti-DNA
antibodies, anti-centromere antibodies, anti-Scl-70 antibod-
ies, C3, C4, CH50, immunoglobulin (Ig)G, IgA, IgM, and
anti-neutrophil cytoplasmic antibodies (ANCA).
• Accelerated or malignant hypertension. Patients with accel-
erated or malignant hypertension often present with TMA.
Patients with aHUS sometimes present with accelerated or
malignant hypertension; thus, when TMA persists after
treatment of hypertension, efforts should be made to differ-
entiate aHUS from these disorders.
• Malignant tumors. Advanced malignant tumors often cause
TMA. In a review of cancer-related TMA cases reported
in the literature, more than 90% had advanced cancers,
including tumors of the gastrointestinal tract, breast, pros-
tate, and lung.24
• Infections. Pneumococcal infections, particularly invasive
pneumococcal infections, cause TMA mostly in children.
Therapeutic plasma exchange may aggravate the condition.
Approximately 90% of patients with pneumococcus-asso-
ciated HUS have positive direct Coombs test results.25 In
addition to pneumococcal infection, infections with human
immunodeficiency virus (HIV), influenza A H1N1 virus,
hepatitis C virus, and cytomegalovirus, as well as pertussis,
varicella, and severe streptococcal infection, have been
reported to cause TMA.16,26,27 Attention should be paid to
the cases where infections with influenza virus and other
infections often trigger the onset of aHUS.28
• Pregnancy-induced HELLP syndrome and eclampsia.
HELLP syndrome and eclampsia usually resolve quickly
after delivery. However, cases of TTP and aHUS triggered
by pregnancy have been reported in the literature. In a
cohort study, patients with aHUS developed HELLP syn-
drome primarily postpartum29; however, the incidence of
aHUS among patients with HELLP syndrome or postpar-
tum HELLP syndrome is unknown.
• Drug-induced TMA. Anti-tumor agents, anti-platelet drugs,
immunosuppressive agents, and other medications may
cause TMA (Table 1).30 Agents suspected of causing TMA
should be tapered or discontinued wherever possible.
• Acute pancreatitis. Acute pancreatitis is a possible or prob-
able precipitating event for TMA episodes.31 In a review
of seven cases of TMA precipitated by acute pancreatitis,
patients responded well to therapeutic plasma exchange.32
• Post-transplant TMA subsequent to hematopoietic stem cell
or organ transplantation. Post-transplant TMA following
hematopoietic stem cell transplantation has been widely
documented. In patients with post-transplant TMA,
ADAMTS13 activities usually do not fall below 10% of
normal, and plasma exchange is not very effective. Typical
interventions include discontinuation or dose reduction of
immunosuppressive calcineurin inhibitors.33 Recent
research revealed a high prevalence of anti-CFH autoanti-
bodies in pediatric patients with hematopoietic stem cell
transplant–associated TMA34; however, the involvement of
complement dysregulation in the pathogenesis of TMA fol-
lowing hematopoietic stem cell transplant requires further
investigation.
Patients with end-stage renal disease due to aHUS who are
undergoing kidney transplant are at high risk of TMA recur-
rence and graft loss. It is therefore advisable to conduct
genetic testing preoperatively in prospective kidney recipients
suspected of having aHUS. TMAs occurring subsequent to
kidney transplant (de novo) involve new onset of aHUS, with
complement abnormalities,35 as well as transplant-induced
TMA.30 The clinical approaches for patients with aHUS
undergoing kidney transplantation and TMA after kidney
transplantation are beyond the scope of this guide; please see
the current consensus.8 The occurrence of TMA has been doc-
umented not only in patients with kidney transplants, but in
those receiving liver, heart, lung, and small intestine trans-
plants.36
Considerations concerning pediatric diagnosis
STEC-HUS should primarily be suspected in children with
TMA aged 6 months or older who manifest severe bloody
diarrhea, because STEC-HUS accounts for approximately 90%
of all pediatric TMA cases. Conditions that predispose pedi-
atric patients to TMA, not accompanied by diarrhea or bloody
stool include pneumococcal and other infections in infants,
and systemic lupus erythematosus and antiphospholipid syn-
drome. When a pediatric patient is diagnosed with TMA, the
physician should immediately examine the possibility of TTP
and determine whether existing medical conditions or oral
medications are causing TMA. If these possibilities are ruled
out, the physician should initiate eculizumab therapy while
Table 1 Examples of medications that may cause TMA (Adopted





Antitumor agents Mitomycin C, gemcitabine, cisplatin,
vascular endothelial growth factor
(VEGF) inhibitors, tyrosine kinase
inhibitors
Immunosuppressants Cyclosporin, tacrolimus, sirolimus
Oral contraceptives
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continuing to investigate whether rarer etiologies are responsi-
ble for TMA.
Laboratory confirmation of aHUS diagnosis
Besides the laboratory data supporting the diagnosis of TMA
mentioned above, low C3 and normal C4 levels strongly sug-
gest activation of the alternative pathway, and hence aHUS.
However, previous data show that low C3 levels are detected
in approximately half of patients with aHUS, and normal C3
levels do not necessarily rule out its diagnosis. To establish a
diagnosis of aHUS, several studies recommend analyses of
CFH, CFI, and CFB levels, and leukocyte expression levels of
CD46 in addition to routine blood C3 and C4 measurements.
However, the levels of these alternative complement mole-
cules do not necessarily lead to the diagnosis of aHUS.6 Quan-
titative hemolytic assay protocols using sheep erythrocytes are
highly sensitive methods for detecting patients with genetic
CFH abnormalities and anti-CFH antibodies.37,38 However,
these protocols are still not practical for use in routine clinical
settings. Urological examination in many patients with aHUS
shows hematuria and proteinuria.
Confirmatory diagnosis of aHUS requires genetic testing
for known causative genes and analysis of anti-CFH antibod-
ies. However, the absence of causative genetic mutations does
not always exclude the diagnosis of aHUS, because approxi-
mately 40% of patients show no known genetic abnormalities.
Physicians caring for patients with suspected aHUS in
Japan are advised to contact the Division of Nephrology and
Endocrinology, University of Tokyo Hospital (ahus-office@u-
min.ac.jp), which will conduct hemolytic assay, anti-CFH anti-
body screening and genetic assays in collaboration with the
National Cerebral and Cardiovascular Center, Research Insti-
tute, Osaka, Japan. These researches are supported as the gov-
ernment-subsidized program, “Observational Study of Atypical
Hemolytic Uremic Syndrome in Japan.”
Treatments
Therapeutic considerations
Since the 1980s, plasma exchange therapy has been the mainstay
method for management of aHUS. This therapy aims to elimi-
nate abnormal complement regulatory proteins and anti-CFH
antibodies, while supplementing normal complement regulatory
proteins. Eculizumab is a humanized monoclonal antibody that
binds to C5 complement protein. Eculizumab suppresses C5
cleavage to C5a and C5b and thereby prevents the production of
the membrane attack complement complex (MAC).
In practical terms, when a patient presents with TMA and
is negative for STEC-HUS and invasive pneumococcal infec-
tion (the latter of which is not indicated for plasma exchange),
the treating physician should start the empirical treatments
described below, while continuing diagnostic efforts. Physi-
cians should also pay attention to systemic management such
as fluid and electrolyte control, blood pressure control, and
supportive therapies for AKI.
If the physician considers plasma exchange appropriate, it
should be started immediately. Daily sessions followed by
gradual tapering of the plasma therapy are recommended.
Plasma infusion may be implemented in pediatric patients in
whom plasma exchange is technically difficult to perform, as
well as in situations where plasma exchange cannot be per-
formed. The tapering of the plasma therapy will generally be
based on improvements in platelet count, LDH and hemoglo-
bin levels.39 Although plasma infusion and plasma exchange
can achieve hematological remission in approximately 70% of
patients with aHUS, long-term outcomes include high inci-
dences of TMA recurrence, progression to end-stage renal fail-
ure, and death.40
If the patient is clinically diagnosed with aHUS after
STEC-HUS, and if TTP and secondary TMA are ruled out,
the physician should consider eculizumab therapy.7 Eculizu-
mab is recommended in the early stages of treatment of pedi-
atric patients with clinically diagnosed aHUS because
pediatric patients have a lower incidence of secondary TMA
than adults and a higher rate of complications related to
catheterization for plasma exchange and plasma infusion.8
Decreased platelet counts observed in patients with aHUS
usually resolve after 1–2 weeks of eculizumab therapy.41–43
In anti-CFH antibody–positive patients, plasma exchange
combined with immunosuppressants or steroids, as compared
to plasma exchange alone, yielded better outcomes with
reduced antibody titers.11 Eculizumab may be considered for
treating aHUS accompanied by extra-renal organ injury.8
Warnings and precautions for eculizumab use
Eculizumab has been shown to elevate the risk of meningo-
coccal infection, and patients should be immunized with
meningococcal vaccine at least 2 weeks prior to receiving ecu-
lizumab. If situations require immediate eculizumab adminis-
tration in a patient who has not been immunized with
meningococcal vaccine, the physician must administer appro-
priate prophylactic antibiotics.
Discontinuation of eculizumab
No expert consensus has been reached regarding the timing of
eculizumab withdrawal after achievement of remission.
One study reviewed 20 cases of aHUS involving eculizu-
mab therapy discontinuation.8 Patients with CFH mutations
and anti-CFH antibody–positive patients had a higher rate of
recurrence. However, among patients with CD46 or CFI muta-
tions and those without known causative genes, no recurrence
was observed during the study period. In a similar review of
24 patients who terminated eculizumab therapy,44 the inci-
dence rate was 25%, and recurrences were noted more fre-
quently in patients with CFH mutation and those positive for
anti-CFH antibodies.
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Available vaccines are insufficient for completely prevent-
ing meningococcal and other types of infections in patients
receiving eculizumab. Eculizumab therapy requires patients to
visit the hospital once every 2 weeks, a requirement that con-
siderably affects their quality of life. Long-term repeated intra-
venous administration often leads to compromised vascular
access. In addition, cost-benefit analyses should be considered
for eculizumab, one of the most expensive drugs on the mar-
ket. Future research on the relationship between genetic muta-
tions and treatment outcomes, and markers for early detection
of recurrence, will shed light on ways of overcoming these
problems.8,44
Outcome
The literature has reported gene-specific differences in
response to therapeutic plasma exchange and in graft survival
after kidney transplant.11 While eculizumab therapy has been
shown to improve treatment outcomes, its gene-specific out-
comes are not well known.
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